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Abstract
The remodeling process in bone yields numerous cytokines and chemokines that mediate crosstalk between osteoblasts
and osteoclasts and also serve to attract and support metastatic tumor cells. The metastatic tumor cells disturb the
equilibrium in bone that manifests as skeletal complications. The Hedgehog (Hh) pathway plays an important role in
skeletogenesis. We hypothesized that the Hh pathway mediates an interaction between tumor cells and osteoblasts and
influences osteoblast differentiation in response to tumor cells. We have determined that breast tumor cells have an
activated Hh pathway characterized by upregulation of the ligand, IHH and transcription factor GLI1. Breast cancer cells
interact with osteoblasts and cause an enhanced differentiation of pre-osteoblasts to osteoblasts that express increased
levels of the osteoclastogenesis factors, RANKL and PTHrP. There is sustained expression of osteoclast-promoting factors,
RANKL and PTHrP, even after the osteoblast differentiation ceases and apoptosis sets in. Moreover, tumor cells that are
deficient in Hh signaling are compromised in their ability to induce osteoblast differentiation and consequently are
inefficient in causing osteolysis. The stimulation of osteoblast differentiation sets the stage for osteoclast differentiation and
overall promotes osteolysis. Thus, in the process of developing newer therapeutic strategies against breast cancer
metastasis to bone it would worthwhile to keep in mind the role of the Hh pathway in osteoblast differentiation in an
otherwise predominant osteolytic phenomenon.
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Introduction
Bone homeostasis depends on the dynamic equilibrium between
osteoblasts and osteoclasts and factors that mediate the crosstalk
between them. Most malignant tumors, particularly breast and
prostate cancers and even other tumor types such as thyroid, lung,
and kidney preferentially metastasize to the skeleton [1]. Once in
the bone, the tumor cells associate with the bone microenviron-
ment and establish a functional entity that alters the balance
coupling bone formation and bone resorption. These changes are
brought about by cytokines and other growth factors produced by
the metastatic tumor cells and can impact both, osteoclasts and
osteoblasts. Some of the well-established factors expressed by
tumor cells that impact bone resorption include TNF-a,- b,
PTHrP, TGF-a,- b, CTGF, CXCR4, IL-11, MMP1 and OPN
[2]. Signaling via the Hedgehog (Hh) pathway has been reported
to upregulate the expression of PTHrP [3] by tumor cells leading
to enhanced osteolysis [4].
In vertebrates the Hh pathway begins with the binding of Hh
ligands (SHH, IHH or DHH) to the Patched receptors on the
membrane. This relieves the inhibitory effect on Smoothened
causing signal transduction into the cytoplasm that activates the
GLI transcription factors to regulate transcription of target genes.
This pathway stimulates osteoblast differentiation [5] and
determination and differentiation of skeletal cells [6].
Our laboratory has recently shown that the Hh pathway plays a
vital role in the crosstalk between breast cancer cells and
osteoclasts [7]. In this study, we have dissected the role of the
Hh pathway in the crosstalk between tumor cells and osteoblasts.
We show that via Hh signaling the tumor cells facilitate osteoblast
differentiation and deposition of mineralized matrix. These
differentiated osteoblasts express RANKL, that together with
OPN and PTHrP tilt the balance in favor of the osteoclasts. As
such, our studies highlight the importance of the delicate balance
between the activities of osteoblasts and osteoclasts and bring forth
the importance of Hh signaling as an important attribute of the
tumor cells’ ability to cause osteolytic metastases.
Materials and Methods
Cell lines
Human fetal osteoblasts, hFOB 1.19 1.19 (ATCC, CRL-11372;
obtained from ATCC, Manassas, VA) cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM/F12; Invitrogen,
Carlsbad, CA), supplemented with 2 mM L-glutamine, 1 mM
sodium pyruvate, 0.02 mM nonessential amino acids, 5% FBS
(Atlanta Biologicals, Norcross, GA), without antibiotics or
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CRL-2594; obtained from ATCC) murine pre-osteoblast cells
capable of differentiation and mineralization in culture (these lines
exhibit high levels of osteoblast differentiation after growth in
ascorbic acid and 3 to 4 mM inorganic phosphate) were
maintained in alpha Minimum Essential Medium (aMEM)
(Mediatech, Herndon, VA) and 10% FBS but devoid of ascorbic
acid. RAW 264.7 (TIB 71; obtained from ATCC) cells, a murine
preosteoclastic line capable of differentiation and mineralization in
culture (in presence of RANKL and M-CSF) were grown in
DMEM with L-glutamine (ATCC, 30-2002).
MDA-MB-231 human metastatic breast cancer cells, SUM1315
(derived from a metastasis in a patient with infiltrating ductal
carcinoma), SUM159 cells (derived from a primary breast tumor
with metaplastic carcinoma) and MDA-MB-435 (435) cells were
cultured as described [7,8]. The generation and culture conditions
of 435 cells stably silenced for OPN (OPNi) or GLI1 (KO1 and
KO4) is previously described [8,9]. All cells were maintained in a
humidified 5% CO2 environment at 37uC. All cultures were
confirmed to be negative for Mycoplasma spp. infection using a
PCR-based test (TaKaRa, Shiga, Japan). While the origin of the
MDA-MB-435 cells is much debated, this cell line has been widely
used to study the mechanisms and consequences of bone
metastases and also to develop interventions in osteolytic
metastasis [10,11].
Harvesting conditioned medium: 3610‘5 cells were seeded in
10 cm culture dishes and grown overnight in their respective
complete media. The following day the cells were washed thrice in
sterile PBS and growth media devoid of serum was added. This
media was collected after 24 hours and used as conditioned media
for the experiments.
Induction of osteoblastic and osteoclastic
differentiation. In order to test the effect of conditioned
medium from the tumor cells on osteoblast differentiation, a
double-strength differentiation medium (DM) was formulated for
MC3T3 E1 Sc-14 cells. It comprised aMEM, 20% FBS, 50 mg/ml
ascorbic acid and 20 mM b-glycerophosphate. Conditioned media
and the double-strength DM were mixed in a 1:1 ratio. 1X DM
was used as control. Similarly a double-strength differentiation
medium was formulated for RAW 264.7 cell lines. It comprised
20% FBS, 50 ng/ml of RANKL (462-TR, R&D, Minneapolis,
MN) and 20 ng/ml of M-CSF (M9160, Sigma, St. Louis, MO)
added to the growth medium. Conditioned media from the tumor
cells was mixed 1:1 with the double-strength DM. 1X DM was
used as control.
Osteoblast differentiation was assessed by alkaline phosphatase
(ALP) activity assay in the perspective of total phosphatase which
was done as previously described [11]. The functional assessment
of osteoblast mineralization was done in triplicate quantified by
staining with Alizarin Red S [3] and scoring the number of
mineralized nodules in 12 independent fields per well.
Apoptosis detection
MC3T3 cells were grown under differentiation conditions along
with conditioned media from tumor cells for 21 days with media
being changed every 3
rd day. At the end of 21 days apoptosis was
assayed using the In Situ Cell Death Detection Kit (Roche,
Indianapolis, IN) following the manufacturers’ protocol for initial
TUNEL staining. Cells were further stained with DAPI (Vecta-
shield, H-1200, Vector Laboratories, Burlingame, CA) and
phalloidin coupled with AlexaFluor 555 (Molecular Probes,
Invitrogen) to visualize the nuclei and cytoskeleton respectively.
The latter staining imparted context to the TUNEL staining. Cells
were visualized under the Nikon TE2000 microscope and TUNEL
positive cells were counted in 12 independent fields (in triplicate)
and expressed as a percentage of total cells in each field of view.
Western Blotting Analysis
Whole cell lysates were collected in NP-40 buffer (150 mM
NaCl, 50 mM Tris, 1% NP-40). Isolation of cytosolic and nuclear
fractions was done as previously reported [15]. Total protein
(30 mg) was resolved by SDS-PAGE gel and transferred to PVDF
membranes. Membranes were immunoblotted overnight at 4uC
with antibodies to either OPN (Cat # 905-629; Assay Designs,
Ann Arbor, MI) or GLI1 (sc-20687; Santa Cruz Biotech, Santa
Cruz, CA). Equal loading was confirmed with anti-b-actin (A3854,
Sigma) antibody. The purity of cytosolic and nuclear fractions was
confirmed with either anti-b-tubulin (clone 9F3; cat#2128; Cell
Signaling, Danvers, MA) or anti-HDAC1 (cat#2062; Cell
Signaling) antibodies respectively. Secreted OPN was assessed by
loading equal quantity of protein from the serum-free conditioned
medium. Corresponding HRP conjugated secondary antibodies
were used for detection; blots were developed with SuperSignal
enhanced chemiluminescence substrate (Pierce, Rockford, IL) and
imaged using a Fuji LAS3000 imager.
Studies with Hh inhibitor, cyclopamine
Serum-free conditioned medium (SFM) harvested from
,3.0610
6 cells after 24 hours was assayed for OPN by
immunoblotting. To test the inhibitory effect of cyclopamine on
the Hh pathway cells were cultured in DMEM supplemented with
0.5% FBS and treated for the indicated time intervals with DMSO
(vehicle control) or cyclopamine (Sigma, St. Louis, MO).
Luciferase Assay
Cells were transfected with the OPN promoter luciferase vector,
pGL3-OPN either alone or in combination with pLNCX or
pLNCX-GLI1 (kindly obtained from Dr. Jingwu Xie, University
of Texas Medical Branch, Galveston, TX) as previously described
[16]. Empty pGL3 vector was used as control. Hh ligands were
added to the well 6 hours prior to harvesting the cells (,33 hours
of initiation of transfection) for assay. Readings were normalized to
total protein content. Each parameter was studied in triplicate and
the experiment repeated at least 3 times.
Quantitative RT-PCR (qRT-PCR)
cDNA was generated using High Capacity Reverse Transcrip-
tase Kit (Applied Biosystems, Foster City, CA). Real time PCR
was performed using a BioRad iQ5 Real-Time Detection system
(Bio-Rad, Hercules, CA). All reactions were done in triplicate.
OPN transcript levels were normalized to GAPDH levels (dCT)
which was used to calculate changes in OPN expression (2-ddCT).
To analyze the effect of cyclopamine treatment on OPN
expression untreated samples were set as calibrator (control) and
compared to their respective treated samples. The primers used
included Spp1 (OPN) (Mm 00436767_m1); Bglap (osteocalcin)
(Mm 01741771_g1); IBSP (Mm 00492555_m1); PTHrP (Mm
00433057_m1); RANKL (Mm 00441906_m1); GAPDH (Mm
99999915_g1).
Animal studies
One million MDA-MB-435 cells suspended in HBSS (Invitro-
gen) were injected into the left cardiac ventricle of 6-week old
female athymic nude mice (Hsd: Athymic Nude-Foxn1
nu; Harlan,
Indianapolis, IN). The success of the intracardiac injection was
assessed by the drawback of bright red arterial blood into the
syringe immediately before and after injection, in contrast to
Hedgehog Pathway and Osteoblast Differentiation
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mice were scored for each group. Mice were euthanized 5 weeks
later. Radiographic images were acquired using a small animal
radiology equipment Acoma model PX 20N (72 KVP, 20 MA).
The images were examined by ABR-Board certified radiologist
(SK). Experiments were conducted under protocol approved by
the Institutional Animal Care and Use Committee (IACUC) of the
University of South Alabama, Mobile.
Immunohistochemical analyses
We obtained breast tumor tissue microarrays from the NCI
Cooperative Breast Cancer tissue Resource (CBCTR). The tissues
were immunohistochemically stained for IHH and GLI1.
Specifically, immunohistochemical staining was performed using
the streptavidin biotin complex method with 3,39-diaminobenzi-
dine (DAB) chromogen using Dako LSAB+ System-HRP reagents
(K4065) (which included a 3% hydrogen peroxide peroxidase
block) in a Dako Autostainer Plus automated immunostainer
(Glostrup, Denmark). Pretreatment for heat induced antigen
retrieval was performed with a Thermo Fisher Scientific Lab
Vision PT Module (Fremont, CA). Blocking for nonspecific
binding was performed with an avidin/biotin blocking kit (SP-
2001; Vector Laboratories, Burlingame, CA). The following
antibodies were used: IHH (ab39634; Abcam, Cambridge, MA)
and GLI1 (ab7523; Abcam). The intensity of cytoplasmic staining
was quantitated with computer-assisted image analysis in a Dako
ACIS III Image Analysis System (Glostrup, Denmark).
Statistical Analysis
Statistical analyses were done using the t-test or ANOVA, per
the mandates for each dataset, using GraphPad Prism 4 software.
Statistical significance was determined if the analysis reached 95%
confidence. In all figures the error bars represent standard error of
the mean (S.E.M.). The exact p-values are listed in the
corresponding figure legends.
Results
Expression of GLI1 and IHH is upregulated in breast
cancer
Using immunohistochemical analyses, we assessed the expres-
sion of the Hh ligand, IHH and the transcription factor GLI1 in a
tissue array comprising 75 breast cancer tissues and 9 tissues
representing normal breast. While the staining intensity of IHH
was comparable (p.0.05) in normal tissues and in tissues derived
from Ductal Carcinoma In Situ (DCIS), the tissues derived from
invasive cancer (representing Infiltrating Ductal Carcinoma
Grades II–IV) and from metastatic breast cancer exhibited
significantly (p,0.0001) increased staining intensity for IHH
(Figure 1A; images a and b). Similarly, the staining intensity of
GLI1 in tissues from invasive cancer and from metastatic cancer
were significantly greater (p,0.0001) compared to normal tissues
(Figure 1B; images c and d).
Hh signaling stimulates osteoblast differentiation and
mineralization activity
In order to assess the effect of Hh signaling on the formation of
osteoblasts, we used the monopotential cell line, MC3T3-E1,
which is a clonal osteoblastic cell line isolated from calvariae of a
late stage mouse embryo. These cells express various osteoblast
functions including formation of mineralized bone nodules in long-
term culture. The addition of Hh ligands, SHH and IHH to the
DM of the MC3T3 cells stimulated differentiation as seen by the
increase (p,0.0001) in the ALP activity (Figure 2A). The
resultant osteoblasts exhibited intense staining by Alizarin Red S
(Figure S1A) indicating the presence of mineralized nodules.
Figure 1. The Hh pathway is activated in breast tumors. Breast cancer tissues (n=75) and normal breast tissues (n=9) were
immunohistochemically stained for (A) IHH and (B) GLI1 expression. The intensity of cytoplasmic staining was quantitated with computer-assisted
image analysis in a Dako ACIS III Image Analysis System (Glostrup, Denmark). Staining intensities were recorded and represented as a scatter plot. The
staining intensities indicating expression levels of IHH and GLI1 were significantly greater (p,0.0001) in the tissues derived from invasive cancer
(representing Infiltrating Ductal Carcinoma Grades II–IV) and from metastatic breast cancer (DM) relative to normal tissues and tissues derived from
Ductal Carcinoma In Situ (DCIS). Panels a and b represent normal breast tissue and invasive breast cancer stained for IHH. Panels c and d represent
normal breast tissue and invasive breast cancer stained for GLI1.
doi:10.1371/journal.pone.0034374.g001
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mineralized nodules formed in the presence of IHH and SHH
(Figure 2B). This was accompanied by an increase (p,0.005) in
the expression of markers of terminally differentiated osteoblasts
[12,13], bonesialoprotein (BSP) and osteocalcin (Figure 2C),
indicating that stimulating Hh signaling promotes osteoblast
differentiation and mineralization activity.
Hh signaling upregulates OPN in osteoblasts
We have previously reported that Hh signaling induces the
expression of OPN [8]. OPN promotes adhesion of osteoblasts
allowing them to function in osteogenesis [14,15,16]. We treated
two osteoblast-forming cells, hFOB 1.19 and MC3T3 with two Hh
ligands, SHH and IHH and assessed the effect on OPN promoter
activity. Both ligands caused an upregulation in OPN promoter
activity (p,0.0001) (Figure 3A). Treatment with the Hh
inhibitor, cyclopamine, keeps GLI1 sequestered in the cytosolic
compartment (Figures S1B & C) simultaneous with a reduction
in the levels of OPN transcript levels (p,0.0001) (Figure 3B),
total OPN protein expression (Figure 3C) and secreted OPN
(Figure 3D) in the pre-osteoblasts.
Hh signaling in tumor cells stimulates differentiation of
osteoblasts as an early event and enhances expression of
RANKL and PTHrP
Tumor cells express Hh ligands [7]. In order to determine the
role of the Hh pathway in mediating the crosstalk between tumor
cells and osteoblasts, we assessed the effect of conditioned medium
from the tumor cells on MC3T3 osteoblast differentiation after 2
weeks using an ALP activity assay. Relative to DM alone,
conditioned medium from the tumor cells caused a significant
(p,0.001) increase in the ALP activity in 2 weeks. The 5E1
antibody blocks binding of all three mammalian Hh ligands to
Ptc1 with low nanomolar affinity, thereby inhibiting Hh signaling
[17]. Depleting the Hh ligands from the conditioned medium of
the tumor cells using the neutralizing 5E1 antibody caused a
decrease in the ALP activity of the differentiated osteoblasts. While
the decrease was apparent, although not statistically significant
with respect to the conditioned medium from MDA-MB-231 and
MDA-MB-435 cells, the decrease was statistically significant
(p,0.05) with respect to conditioned medium from SUM1315
and SUM159 cells (Figure 4A).
Simultaneous with the reduction in ALP activity, depletion of
Hh ligands from the differentiation conditions caused a significant
decrease (p,0.05) in the expression of (differentiated) osteoblastic
proteins, BSP and osteocalcin (Figure S1D). Functionally, the
ability of the osteoblasts to form mineralized nodules was
significantly increased (p,0.0001) in response to conditioned
medium from tumor cells relative to DM alone. Addition of the
5E1 antibody to the differentiation conditions resulted in a
significant decrease (p,0.001) in the ability of the tumor cell-
conditioned medium to elicit osteoblast mineralization activity
(Figure 4B).
Differentiated osteoblasts express RANKL and PTHrP, both of
which have been reported to play an important role in promoting
osteoclast differentiation [18,19]. Thus, we queried the expression
of these two molecules under the conditions used for differenti-
Figure 2. Activation of Hh signaling promotes differentiation
and mineralization activity of osteoblasts. MC3T3 E1 Sc-14 cells
were grown in differentiation medium (DM) supplemented with either
with 100 nM recombinant SHH or IHH or without. Cells grown in normal
growth medium were used as control. (A) Differentiation was assessed
by alkaline phosphatase (ALP) assay. Under differentiation conditions
that included recombinant IHH or SHH, the ALP activity was
significantly greater ({ indicates p,0.0001) relative to DM alone. (B)
Relative to control (growth medium), DM induced the formation of
mineralized nodules. Relative to DM the media spiked with recombi-
nant IHH and SHH supports the formation of significantly greater
number of mineralized nodules ({ indicates p=0.012 and 0.002,
respectively). The number of nodules formed due to each treatment
is represented as a percentage of the total number of cells present in
each field of view. Control represents growth medium. The number of
mineralized nodules in 12 independent fields per well were scored. (C)
The expression of osteoblast differentiation marker genes, BSP ({
indicates p=0.0027) and osteocalcin ({ indicates p=0.0004) is
significantly elevated in presence of SHH at the end of 14 days. Cells
were harvested and RNA extracted which was used in real time
quantitative RT-PCR assay. The fold change in expression is represented
relative to control (growth medium).
doi:10.1371/journal.pone.0034374.g002
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cells, after 2 weeks of differentiation, the osteoblasts expressed
significantly elevated (p,0.01) levels of RANKL and PTHrP
(Figure 4 C & D). Depletion of Hh ligands from the conditioned
medium of the tumor cells resulted in a significant decrease
(p,0.001) in the levels of RANKL and PTHrP elicited by the
conditioned medium. Thus, while Hh ligands from the tumor cell-
conditioned medium contributed to osteoblast differentiation, their
impact was more pronounced on the expression of RANKL and
PTHrP by the differentiated osteoblasts.
OPN expressed by the tumor cells influences osteoblast
activity
OPN, a secreted protein expressed by tumor cells, has been
implicated as an important regulator of osteoblast differentiation
[20]. Both, SUM1315 and MDA-MB-435 cells express OPN [7].
In order to assess the effect of tumor cell-derived OPN on the
osteoblasts, we first abrogated OPN expression using shRNA [9]
and harvested the cell-free conditioned medium from these cells.
Osteoblast differentiation was studied in presence of this
conditioned medium and we assessed the expression of BSP and
osteocalcin as indicators of osteoblast differentiation and measured
osteoblast differentiation activity by enumerating the mineralized
nodules formed. The conditioned medium from the SUM1315-
OPNi and 435-OPNi cells was less efficient (p,0.005) in inducing
osteoblast differentiation and mineralization (Figure 5 A–C).
Likewise, the expression of RANKL and PTHrP by the osteoblasts
was significantly compromised (p,0.0001) under differentiation
conditions with conditioned medium from tumor cell that were
depleted of OPN expression (Figure S2A). As such, OPN
expressed by the tumor cells plays a vital role in the crosstalk
between tumor cells and osteoblasts.
Hh signaling in tumor cells impacts their ability to induce
osteoblast differentiation
We have recently published that Hh signaling in breast cancer
cells also plays a vital role in communication between the breast
cancer cells and osteoclasts [7]. In order to assess the role of Hh
signaling in tumor cells on their ability to elicit osteoblast
differentiation, we abrogated the expression of GLI1 from the
tumor cells by shRNA [8]. Conditioned medium from the GLI1-
silenced cells was inefficient (p,0.005) in inducing osteoblast
differentiation as represented in the expression of BSP, osteocalcin
(Figure 5A & B) and the osteoclast differentiation-promoting
RANKL and PTHrP proteins (p,0.05) (Figure S2A). Further,
the mineralization activity of the osteoblasts was also significantly
impaired (p,0.05) when the differentiation was elicited for 2
weeks in presence of conditioned medium from cancer cells that
were silenced for GLI1 (Figure 5C), suggesting that active Hh
signaling in the tumor cells is vital to their ability to induce
osteoblast differentiation.
Extended differentiation in presence of tumor cell-
conditioned media promotes osteoblast apoptosis
Thus far, our data suggests that soluble factors that include
OPN and the Hh ligands secreted by tumor cells enhance
osteoblast differentiation and mineralization activity. This starkly
contradicts the well-established fact that tumor cells causes
osteoblasts to undergo apoptosis [11]. Notably, these reported
studies conducted osteoblast differentiation for longer time periods
i.e. 3 weeks or longer. Thus, in order to capture the full impact of
Figure 3. Hh signaling regulates OPN expression in osteoblastic cells. (A) Hh ligands significantly increase the activity of OPN promoter in
the preosteoblastic cell lines hFOB 1.19 and MC3T3 E1 Sc-14 ({ indicates p,0.0001 for all indicated groups). Cells were transfected with OPN
promoter, treated with Hh ligands at the indicated concentrations and assessed for luciferase activity. (B) The Hh pathway inhibitor, cyclopamine
(20 mg/ml), decreased the expression of OPN transcript ({ indicates p,0.0001). hFOB 1.19 cells were treated with cyclopamine for 24 hours and
assessed by quantitative real time RT-PCR for OPN expression. The expression of total OPN, from the cell lysate (C) as well as secreted OPN (D)i s
decreased in presence of cyclopamine. The decrease in the secreted OPN protein level is both, dose (5, 10 and 20 mM) and time dependent. hFOB
1.19 cells were treated with cyclopamine (20 mM for 24 hours; in panel C) and at theindicated concentrations and time intervals in panel D and
assessed for expression of OPN by immunoblotting.
doi:10.1371/journal.pone.0034374.g003
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parallel experiments that were assessed 3 weeks post induction of
differentiation. While differentiation and mineralization activity
were already attained at 14 days, the levels of BSP and osteocalcin
plummeted sharply (p,0.001) at 3 weeks relative to their
expression at 2 weeks in differentiation conditions comprising
conditioned media from tumor cells (Figure 6A & B). In contrast,
the expression of PTHrP significantly increased (p,0.001) in
presence of conditioned medium from 3 of the 4 tumor cell lines,
whereas RANKL showed variation in the all the four cell systems
investigated (Figure 6C & D). We also assessed the incidence of
apoptosis following 21 days of differentiation in the presence of
conditioned media from tumor cells. Relative to DM alone, the
conditioned medium from all four tumor cells caused a significant
increase (p,0.05) in the incidence of apoptosis (Figure 6E &
Figure S2B), thus corroborating with the published reports.
Thus, the data suggests that osteoblasts express osteoclastogenic
factors, PTHrP and RANKL in response to OPN and Hh
signaling triggered by tumor cells (Figures 4, 5 & Figure S2A).
Hh signaling in tumor cells enhances the incidence and
intensity of osteolytic metastases
Intuitively, our data suggests that tumor cells initiate osteoblast
differentiation and the expression of osteoclastogenic factors as an
early event, followed by elimination of osteoblasts later. Thus, the
overall microenvironment appears to shift in favor of osteoclas-
Figure 4. Hh ligands produced by tumor cells impacts the osteoblast differentiation and expression of RANKL and PTHrP. (A)
Conditioned media from all four tumor cell lines caused a significant increase in ALP activity of MC3T3-derived osteoblasts: SUM1315 ({p=0.0002);
MDA-MB-231 ({p=0.0035), SUM159 ({p=0.0005), MDA-MB-435 ({p=0.0009). Addition of the Hh neutralizing antibody, 5E1, caused a reduction in
ALP activity. SUM1315+5E1 (‘p=0.014); MDA-MB-231+5E1 (p=0.12), SUM159+5E1 (‘p=0.04), MDA-MB-435+5E1 (p=0.6). (B) Tumor cell-conditioned
media stimulated mineralization activity of the MC3T3-derived osteoblasts as evidenced by the numbers of mineralized nodules after Alizarin Red S
staining. Nodules were counted in 12 independent fields and expressed as a percentage of the total number of cells in the field of view. SUM1315
({p=0.0013); MDA-MB-231 (p.0.05), SUM159 ({p=0.018), MDA-MB-435 ({p,0.0001). Addition of the Hh neutralizing antibody caused a reduction in
numbers of mineralized nodules. SUM1315+5E1 (‘p=0.02); MDA-MB-231+5E1 (p=0.0005), SUM159+5E1 (p=0.17), MDA-MB-435+5E1 (p,0.0001). (C)
The expression of RANKL by the differentiated MC3T3-derived osteoblasts was significantly increased in presence of tumor cell-conditioned medium.
({p=0.0013, for all four tumor cell lines). Neutralization of the Hh ligand with the 5E1 antibody caused a reduction in the levels of RANKL expressed.
SUM1315+5E1 (‘p=0.0004); MDA-MB-231+5E1 (‘p=0.0002), SUM159+5E1 (‘p=0.0003), MDA-MB-435+5E1 (‘p=0.0002). (D) The expression of PTHrP
by the MC3T3-derived osteoblasts was notably greater in presence of conditioned medium from the tumor cells (p,0.0001 for all tumor cells).
Neutralization of Hh ligand caused a significant decrease in the levels of PTHrP. SUM1315+5E1 (‘p=0.04); MDA-MB-231+5E1 (‘p=0.0001),
SUM159+5E1 (‘p=0.01), MDA-MB-435+5E1 (‘p,0.0001). The expression of RANKL and PTHrP were assessed by real time qRT-PCR after 14 days of
differentiation. Data is expressed relative to control (growth medium).
doi:10.1371/journal.pone.0034374.g004
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the tumor cells with respect to osteolytic metastasis, we injected
tumor cells via the left ventricle and assessed the incidence of
osteolytic metastases at the tibio-femoral junction 5 weeks later. In
the mice injected with 435-vector control cells, we saw metastasis
in 100% of the mice injected. In contrast, relative to the mice
injected with control cells, the incidence in mice injected with
tumor cells stably silenced for GLI1 was reduced to 60% (each
knee is scored as an incident; Figure 7 and Figure S2C).
Overall, there was a decrease in the intensity of the osteolytic
metastasis as well. The data suggests that Hh signaling in the
tumor cells is essential to the development of osteolytic metastases.
These cells are also capable of directly activating osteoclast
differentiation (assessed by TRAP staining) and stimulating
resorption activity (Figures S2D & E). Moreover, the active
Hh signaling and expression of OPN are important attributes for
the tumor cells to activate osteoclast differentiation and resorptive
activity. Thus, the data suggests that Hh signaling in the tumor
cells can directly impact the ability of the cells to cause osteolysis.
Discussion
The Hh pathway plays an essential function in regulating cell
fate and in developmental patterning in animals and humans. This
pathway is also important in the formation of the skeleton. During
skeletogenesis and endochondral ossification Hh signaling coordi-
nates growth and differentiation [21,22,23]. In adult animals,
systemic administration of the ligand SHH, resulted in a primary
increase in osteoblasts and their precursors. Interestingly, this was
accompanied by an enhanced osteoclastogenic potential and
decreased bone volume due to upregulation of the PTH/PTHrP
receptor. Thus, Hh signaling in the adult bone milieu caused
stimulatory effects on osteoprogenitors and osteoblasts resulting in
bone remodeling and reduced bone strength because of a
secondary increase in osteoclastogenesis [24].
The bone is a common site of metastasis for several
malignancies. The impact of metastasized tumor cells in the bone
disrupts the balance between the activities of the osteoclasts and
osteoblasts. Radiographically, the bone lesions are classified as
being osteolytic (bone loss) or osteosclerotic (bone formation) or
mixed. Breast cancer bone metastases are usually osteolytic,
characterized by excess bone turnover and consequent bone
resorption. This is concomitant with the apoptosis and elimination
of osteoblasts. In fact, several papers suggest that breast cancer
cells limit osteoblasts by either inducing apoptosis or interfering
with normal function and thus facilitating osteolysis through
increased osteoclast activity [11,25,26,27]. Paradoxically, it must
be noted that the basic trigger for the differentiation of pre-
osteoclasts to osteoclasts is supplied by the osteoblasts. Osteoblasts
produce M-CSF and RANKL that promote pre-osteoclasts to
Figure 5. Tumor cells competent for Hh signaling and OPN
expression are efficient at inducing osteoblast differentiation.
Stable silencing of OPN (OPNi) or GLI1 (KD2 and KO1) from SUM1315
and MDA-MB-435 tumor cells significantly reduces the expression of (A)
BSP [Relative to SUM1315, SUM1315-OPNi (‘p=0.008) and KD2
(‘p=0.0004) show lower BSP; Relative to MDA-MB-435, 435-OPNi and
KO1 have decreased BSP (‘p,0.0001)], (B) osteocalcin [SUM1315-OPNi
(‘p=0.0013) and KD2 (‘p=0.0004); 435-OPNi and KO1 (‘p,0.0001)],
and (C) the mineralization capacity of the osteoblasts [SUM1315-OPNi
(‘p=0.04) and KD2 (‘p=0.04); 435-OPNi (‘p,0.0001) and KO1
(‘p=0.0003)]. The expression of BSP and osteocalcin were assessed
by real time qRT-PCR and the nodules were quantified (in 12
independent fields in triplicate) after Alizarin Red S staining after 14
days of differentiation.
doi:10.1371/journal.pone.0034374.g005
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promotes osteoblast apoptosis. MC3T3 cells were grown in differentiation supplemented with conditioned media from cancer cells for either 14
days or 21days. At the end of each time point RNA was harvested from the differentiated osteoblastic cells and levels of BSP, osteocalcin, PTHrP and
RANKL were assessed by qRT-PCR. (A) There is a significant decrease in the levels of BSP at 21 days relative to 14 days of differentiation for all four
tumor cell lines assessed ({p,0.0001 for all tumor cells). (B)The levels of osteocalcin significantly decrease at 21 days relative to 14 days of
differentiation ({p,0.0001 for all tumor cells). (C) The levels of PTHrP remained at elevated levels at 21 days post-initiation of differentiation
(SUM1315: {p=0.0005; MDA-MB-231: {p=0.0006; SUM159: p.0.05; MDA-MB-435: {p,0.0001). (D) The levels of RANKL also remained elevated 21
days after differentiation. (SUM1315: {p=0.0023; MDA-MB-231: p=0.07; SUM159: {p=0.0002; MDA-MB-435: {p=0.004). The levels of RANKL and
PTHrP were assessed by qRT-PCR. (E) Assessment of apoptosis was done at the end of 21 days post initiation of differentiation. Fluorescein
conjugated TUNEL staining was performed to assay for apoptosis followed by nuclear staining with DAPI and cytoskeleton staining with phalloidin.
Percentage of apoptotic cells was calculated as the number of cells with green fluorescence in the nucleus divided by the total number of cells
(represented by the blue DAPI stain) in each field of view. Enhanced apoptosis of osteoblasts was noted in presence of conditioned media from all
tumor cells (SUM1315 ({p=0.005), MDA-MB-231 ({p=0.002), SUM159 ({p=0.01), MDA-MB-435 ({p=0.04)).
doi:10.1371/journal.pone.0034374.g006
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bone and degrade the bone matrix [18]. RANKL and M-CSF
activate a dendritic cell-specific transmembrane protein (DC-
STAMP) that facilitates cell-cell adhesion and cytoskeletal re-
arrangements resulting in a multinucleate osteoclast [28]. Thus,
the availability of differentiated osteoblasts is vital to the
development of active osteoclasts. Likewise, osteoclasts express
BMPs that promote recruitment and proliferation of osteoblasts at
resorption sites [19].
Thus, given the vital role that osteoblasts play in facilitating
osteoclast activity, the elimination of osteoblasts by the tumor cells
seems counter intuitive and warrants further understanding of the
delicate balance between osteoblast and osteoblasts. In this study,
we have investigated the role of Hh signaling in tumor cells on the
interaction between tumor cells and osteoblasts. We have
determined that breast cancer cells express elevated staining
intensities for the Hh ligand IHH and the transcription factor,
GLI1, indicating that the Hh pathway is activated in breast tumor
cells. The upregulated expression of Hh ligands and GLI1 has also
been studied by other investigators. In studies from independent
laboratories, the expression of GLI1 and Hh ligand(s) has been
shown to be indicative of activated Hh signaling and is associated
with poorly differentiated phenotype and increased metastatic
ability [29]. This has been found to be reported in multiple
malignancies. As recently reported by O’Toole and others [30], a
paracrine signature, encompassing high epithelial Hh ligand and
high stromal GLI1, was an independent predictor for overall
survival in multivariate analysis. Specifically, expression of IHH,
PTCH and GLI1/2 has been determined to be correlated with
enhanced proliferation in invasive breast carcinoma, node
metastasis and clinical stage of breast cancer [31]. In other
studies, the nuclear localization of GLI1 has been found to be
associated with the expression of estrogen receptor-a [32,33].
Upregulated GLI1 expression was also found to be a reliable
indicator of constitutive Hh activation in surgically-resected ER-a-
negative breast cancer patients [34]. Thus, our observations are in
agreement with previous reports and indicate a constitutive Hh
signaling in advanced breast cancer.
In order to determine the consequences of the interaction
between tumor cells and osteoblasts, we investigated osteoblast
differentiation at early (14 days) and late (21 days) post-initiation of
differentiation in presence of conditioned media from tumor cells.
While Hh ligands expressed by the tumor cells enhanced
osteoblastogenesis and mineralization activity as an early event,
we also observed enhanced expression of osteoclastogenesis-
promoting factors viz. RANKL and PTHrP in the differentiated
osteoblasts. Likewise, OPN expressed by the tumor cells also
stimulated osteoblast differentiation. Tumor cells with a competent
Hh pathway were more potent at inducing osteoblast differenti-
ation and expression of RANKL and PTHrP.
While the expression of osteoblast differentiation markers, BSP
and osteocalcin dwindled at a later event (21 days) characterized
by increased apoptosis of the osteoblasts, the expression of
RANKL and PTHrP continued to be robust, suggesting that the
osteoblasts were expressing factors that would propel osteoclasto-
genesis. Thus, our data suggest that tumor cells initially enhance
the differentiation of osteoblasts that in turn, express osteoclasto-
genesis enhancing factors. Later, as the osteoblasts get eliminated,
the availability of RANKL and PTHrP creates an environment
that will stimulate osteoclast differentiation and activity. Thus, an
active Hh signaling in the tumor cells facilitates the generation of
an osteoclast-stimulating milieu by initially kick-starting osteoblast
development. This is apparent in the fact that ablating GLI1
severely compromised the ability of the tumor cells to form
osteolytic metastasis in an experimental model of bone metastasis.
Miao et al [35,36] have previously reported a role for osteoblast-
derived PTHrP as a physiological regulator of bone remodeling.
PTHrP is produced by cells of early osteoblast lineage that do not
express PTH-receptor. PTHrP acts on receptor-positive commit-
ted preosteoblasts, and these cells respond by differentiating into
mature osteoblasts. PTHrP acts directly on mature osteoblasts and
osteocytes to prevent their apoptosis and is also required to
enhance production of RANKL by PTHR1-positive pre-osteo-
blasts. As a result, osteoclast formation is promoted by interaction
of the membrane molecule, RANKL, with its receptor, RANK. It
is surmised that a fine balance or spatiotemporal control
mechanisms exist to ensure availability of PTHrP for enhancing
osteoblast differentiation, as persistently increased local PTHrP
levels would favor increased osteoclast formation, through
stimulation of RANKL production resulting in increased bone
resorption, and high-turnover osteoporosis [19]. In fact, our results
show a steady expression of PTHrP by osteoblasts (at 21 days) and
are supported by the fact that Hh signaling competent tumor cells
in fact, cause radiographically evident osteolysis in animal models.
Skeletal integrity is an essential survival function of mammals.
Our findings reveal that the tumor cells can alter the balance
Figure 7. Active Hh signaling in the tumor cells is vital to their ability to cause osteolysis. MDA-MB-435 tumor cells were injected into the
left cardiac ventricle of athymic mice; mice were euthanized 4–6 weeks later and radiographically imaged and assessed for osteolysis at the tibio-
femoral junction. As represented in the Table, cells that were silenced for GLI1 expression showed an attenuated ability of osteolysis. The percent
incidence of osteolysis is depicted in the adjacent graph.
doi:10.1371/journal.pone.0034374.g007
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signaling. Thus, given the fact that breast cancer cells express
Hh ligands (Figure S1) and that Hh signaling propels breast
cancer progression [33,37,38,39], our studies imply that admin-
istration of pharmacological Hh inhibitors can inhibit Hh
signaling in breast cancer cells, osteoblasts and osteoclasts and
may reduce breast cancer-mediated bone loss in metastatic
disease. This strategy targets the tumor cells as well as the bone
and its microenvironment [40] and can reduce tumor burden and
tumor-derived bone lesions.
Supporting Information
Figure S1 (A) To visualize differentiated osteoblasts,
cells were stained with Alizarin Red and wells scanned
at the end of 14 days of differentiation process. Shown are
representative well scan images and photomicrographs of
differentiated osteoblasts. A representative mineralized nodule is
encircled. (B) The Hh pathway inhibitor, cyclopamine
restricts GLI1 to the cytosol. hFOB cells were cultured in
absence (control) or in presence of cyclopamine (20 mM) for 24 h.
The cells were fixed in 4% formaldehyde, permeabilized in 0.5%
Triton-X and probed with anti-GLI1 antibody followed Alexa.-
Fluor 488-coupled second antibody (Molecular Probes). Cells were
observed under either DIC or fluorescence (at 488 nm for
Alexa.Fluor) and 461 nm for DAPI. Photomicrographs were
acquired at using Axiovert 200 M Fluorescence Microscope
(Zeiss). In the composite shown, GLI1 is stained green. (C)
Cyclopamine treatment causes GLI1 to accumulate in
the cytosol. Nuclear and cytosolic fractions were prepared after
treating hFOB cells with cyclopamine. HDAC1 is used as a
marker of purity of the nuclear fraction. (D) Hh ligands
produced by the tumor cells upregulates expression of
BSP and osteocalcin in the osteoblasts 14 days after
initiation of differentiation. Deprivation of the Hh ligands
from the tumor cell-conditioned medium using the 5E1 neutral-
izing antibody caused a significant reduction in the levels of BSP
(SUM1315+5E1: ‘p=0.01; 435+5E1: ‘p,0.0001) and osteocalcin
(OC) (SUM1315+5E1: ‘p=0.001; 435+5E1: ‘p,0.0001).
(TIF)
Figure S2 (A) Expression of GLI1 and OPN in the tumor
cells enhances their ability to induce RANKL and PTHrP
by the osteoblasts. Abrogation of GLI1 expression in the
SUM1315 cells reduces the expression of RANKL
(KD2:{p=0.02) and PTHrP (KD2: {p=0.02003) elicited by the
conditioned media from these cells. Likewise, conditioned medium
from MDA-MB-435 cells abrogated for GLI1 was less efficient at
inducing expression of RANKL (KO1: {p,0.0001) and PTHrP
(KO1: {p,0.0001) by the osteoblasts. Ablating expression of OPN
also caused a significant reduction in eliciting the expression of
RANKL (OPNi: {p,0.0001) and PTHrP (OPNi: {p,0.0001) in
osteoblasts. (B) Extended differentiation in presence of
conditioned media from tumor cells promotes osteo-
blast apoptosis. The extent of apoptosis was assessed by
TUNEL staining followed by DAPI and phalloidin counterstain-
ing. Representative images shown depict apoptosis recorded for a:
DM; b: SUM1315; c: MDA-MB-231; d: SUM159; e: MDA-MB-
435. (C) Abrogating GLI1 expression reduces the inci-
dence and intensity of osteolysis inflicted by MDA-MB-
435 cells. Radiographic images (i) and (ii) represent osteolysis in
mice injected with MDA-MB-435-vector control cells. Images (iii)
and (iv) represent absence of evidence of osteolysis in mice
injected with MDA-MB-435-KO1 (silenced for GLI1) cells. Cells
were injected via the intracardiac route. (D) Interfering with
Hh signaling decreases with the ability of tumor cells to
induce osteoclast differentiation. Relative to DM, the
conditioned medium from the MDA-MB-435 cells causes the
development of significantly increased numbers of TRAP-positive
multinucleate osteoclasts ({p=0.0004). There was a significant
reduction in this ability following interference with Hh signaling in
the tumor cells with cyclopamine treatment (‘p,0.0001) or
silencing GLI1 (‘p,0.0001). Silencing OPN from the tumor cells
also significantly reduced (‘p=0.001) their ability to elicit
osteoclast differentiation. Osteoclast differentiation was scored
using the TRAP assay following the manufacturer’s protocol
(Sigma). (E) Interfering with Hh signaling decreases with
the ability of tumor cells to enhance resorptive activity
of osteoclasts. Conditioned medium from the MDA-MB-435
cells significantly enhances ({p=0.006) the ability of DM to
induce resorptive activity of osteoclasts. Cyclopamine treatment
(‘p=0.007) or GLI1-silencing (‘p=0.016) or OPN-silencing
(‘p=0.03) of the tumor cells significantly reduced their ability to
activate the resorptive function of osteoblasts. The ability of the
osteoclasts to resorb bone matrix was tested using osteoclast
activity assay (OAAS plates, Osteogenic Core Technologies).
(TIF)
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